Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366500 | 0.90 | MAOA (0.70) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3366506 | 0.90 | MAOA (0.70) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3364821 | 0.89 | MAOA (0.78) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3366490 | 0.89 | MAOA (0.78) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3366962 | 0.89 | MAOA (0.78) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL16693734 | 0.89 | MAOB (0.80) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3368160 | 0.88 | MAOA (0.79) | MAOAMAOBTP53MAPTLMNA | |
| Sembragiline SCHEMBL2440943 | 0.88 | MAOB (1.00) | MAOAMAOBTP53POLBMAPT | |
| SCHEMBL3368166 | 0.88 | MAOA (0.79) | MAOAMAOBTP53MAPTLMNA | |
| SCHEMBL3367599 | 0.88 | MAOA (0.79) | MAOAMAOBTP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | claimed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOA 2/4885MAOB 1/4885TP53 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.